GHRP-2

Batch #344910Batch # 344910
Report #53445Report # 53445
Tested at99.17% purityTested at 99.17% purity
Size: 5mg
Money Back Guarantee Money Back Guarantee
Satisfaction Guarantee Satisfaction Guarantee
Easy Returns Easy Returns
Secure Ordering Secure Ordering
2-Day Shipping 2-Day Shipping
Third Party Tested Third Party Tested
Batch & Lot Tracking Batch & Lot Tracking

RESEARCH USE ONLY
These compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

About GHRP-2

Synthetic hexapeptide utilized in laboratory investigations of ghrelin receptor (GHS-R1a) binding mechanisms and growth hormone secretagogue pathways. GHRP-2 serves as a research tool for examining peptide-receptor interactions, comparative binding affinity studies, and cellular signaling cascade analysis.

Product Specifications

GHRP-2 Lyophilized Powder in 3ml vial.

Application

Research peptide that has been evaluated in growth hormone studies

Appearance

Solid, white powder in 3mL glass ampule

Chemical Formula

C45H55N9O6

PubChem CID

6918245

CAS Number

158861-67-7

Molecular Weight

817.97 g/mol

Synonyms

Growth Hormone Releasing Peptide-2, GHRP2

Storage

Store at ≤25°C, sealed, away from heat, light, and moisture.

1) Clinical Overview

GHRP-2 (sequence: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic growth hormone secretagogue (GHS) that agonizes the ghrelin receptor (GHS-R1a), stimulating pituitary GH release via a pathway distinct from GHRH and often synergistic with it. In addition to somatotropic effects, human studies show small, context-dependent rises in ACTH/cortisol and prolactin—evidence of hypothalamic involvement. In Japan, the GHRP-2 drug pralmorelin is approved as a diagnostic GH-stimulation agent (GHRP Kaken 100 for Injection). 

2) Human Clinical Findings

Robust GH release; dose response; non-GH pituitary effects. In young and elderly adults, IV GHRP-2 (1–2 μg/kg) provoked strong, dose-related GH rises exceeding those from standard GHRH; both PRL and ACTH/cortisol also increased modestly (less PRL than TRH; ACTH/cortisol similar to hCRH). 

Synergy with GHRH; sustained infusions; 30-day study. In healthy adults, GHRP-2 + GHRH showed clear synergy acutely and during 24-h co-infusion; 30 days of continuous SC GHRP-2 (1 μg/kg·h) in older men and women increased pulsatile GH secretion (>3× on day 1; ~1.8× by day 30) and raised IGF-1, IGFBP-3, and IGFBP-5, with routine safety labs remaining normal. 

Intranasal route and pediatrics. In children with short stature, intranasal GHRP-2 (5–20 μg/kg) elicited significant GH rises; GHRH + GHRP-2 was synergistic. Longer pediatric programs (intranasal spray) have reported growth-rate improvements, though broader peer-review and replication are limited. 

Appetite/energy intake. In lean men, SC GHRP-2 infusion (1 μg/kg·h) for 270 min increased ad libitum food intake ~36% vs saline and raised circulating GH-mirroring ghrelin-like orexigenic effects. 

Physiologic modulators. BMI, sex, gonadal status, and L-arginine can modulate GHRP-2/GHRH synergy and GH amplitudes in adults. 

3) Mechanism & Effects

GHRP-2 activates GHS-R1a (the ghrelin receptor), driving GH release at pituitary somatotrophs and via hypothalamic circuits (functional antagonism of somatostatin and facilitation of endogenous GHRH likely contribute), which explains synergy with exogenous GHRH. Beyond GH, transient ACTH/cortisol and PRL rises occur in some protocols. The hexapeptide’s sequence and pharmacology are well described in receptor/ligand literature and peptide catalogs. 

4) Safety & Considerations

Short-term trials (diagnostic dosing; controlled infusions) generally report good tolerability with predictable endocrine shifts (↑GH; occasional ↑ACTH/cortisol/PRL), and normal routine safety labs in the 30-day SC study of older adults. Long-term safety outside trials remains insufficiently defined. 

Regulatory status / quality: Pralmorelin is an approved diagnostic in Japan (injectable). Products sold online for non-diagnostic use are unregulated; quality (identity, sterility, endotoxin) can vary. 

FDA cautions (U.S. compounding context): FDA has noted reports (causality not established) of adverse events in recipients of GHRP-2, including altered insulin needs, infection, pancreatitis, and deaths in critically ill subjects—underscoring the need for medical oversight in any research use. 

Sport / anti-doping: GHRP-2 (pralmorelin) and all GHRPs are prohibited at all times under WADA S2 (Peptide hormones, growth factors, related substances). 

References

  1. Comparative endocrine effects: Arvat E, et al. Effects of GHRP-2 and hexarelin on GH, PRL, ACTH, cortisol in man. J Endocrinol Invest. 1997. (Dose/age effects; ACTH/cortisol & PRL responses). 
  2. Synergy & extended exposure: Bowers CY, et al. 30-day continuous SC GHRP-2 in older adults; synergy with GHRH; IGF-axis increases. J Clin Endocrinol Metab. 2004. 
  3. Intranasal & pediatric data: Pihoker C, et al. IV and intranasal GHRP-2 in short-stature children; synergy with GHRH. J Clin Endocrinol Metab. 1995. 
  4. Appetite/energy intake: Laferrère B, et al. GHRP-2 increases food intake in healthy men. J Clin Endocrinol Metab. 2005. 
  5. Mechanism / receptor: Reviews on GHS-R1a biology and expression. 
  6. Regulatory/diagnostic: PMDA Japan listing (GHRP Kaken 100—pralmorelin hydrochloride, injection). 
  7. Anti-doping: WADA 2025 Prohibited List—lists GHRP-2 (pralmorelin) among banned GHRPs. 

You ask,
we answer.